Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease
暂无分享,去创建一个
Ann M. Johnson | P. Gabow | W. D. Kaehny | W. Kimberling | D. Lezotte | I. Duley | Richard H. Jones | Irene T. Duley
[1] C. Patrono,et al. Evidence for a renal origin of urinary thromboxane B2 in health and disease. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.
[2] S. Yokoyama,et al. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. , 1984, Arteriosclerosis.
[3] H. Mabuchi,et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). , 1987, Atherosclerosis.
[4] M. Karnovsky,et al. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. , 1987, Kidney international.
[5] T. Miyahara,et al. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). , 1988, Nihon Jinzo Gakkai shi.
[6] S. Klahr,et al. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] G. Remuzzi,et al. Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome , 1990, The Lancet.
[8] R. Hené,et al. Partial remission of nephrotic syndrome in patient on long-term simvastatin , 1990, The Lancet.
[9] B. Kasiske,et al. Hyperlipidemia and progressive renal disease. , 1991, Kidney international. Supplement.
[10] J. Moorhead. Lipids and progressive kidney disease. , 1991, Kidney international. Supplement.